Coherus Oncology (CHRS) Inventory Average (2019 - 2026)

Coherus Oncology has disclosed Inventory Average across 8 years of filings, most recently posting $4.0 million for Q1 2026.

• Inventory Average for Q1 2026 came in at $4.0 million, up 3.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (up 3.52% YoY), and the FY2025 annual result was $3.7 million, down 88.96% from the prior year.
• Inventory Average came in at $4.0 million for Q1 2026 at Coherus Oncology, up from $2.6 million in the prior quarter.
• In the past five years, Inventory Average ranged from a high of $65.4 million in Q3 2023 to a low of $2.6 million in Q4 2025.
• The 5-year median for Inventory Average is $34.3 million (2022), against an average of $34.6 million.
• Across the five-year window, Inventory Average jumped 119.92% in 2023 and plunged 94.02% in 2025, its largest moves.
• Coherus Oncology's Inventory Average stood at $33.3 million in 2022, then soared by 94.54% to $64.7 million in 2023, then sank by 59.93% to $25.9 million in 2024, then sank by 89.93% to $2.6 million in 2025, then surged by 53.2% to $4.0 million in 2026.
• The last three Inventory Average figures came in at $4.0 million (Q1 2026), $2.6 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.